OrganOx Unveils Advanced Research, Development, and Production Center in Oxford, UK

Thursday, May 23, 2024

OrganOx, a pioneer in medical technology specializing in organ preservation for transplantation and treatment of acute organ failure.

Excited to announce the opening of its new 18,000 square-foot global headquarters for research, development, and production in Oxford, UK. Founded in 2008 as a spin-out from the University of Oxford, OrganOx created the world’s first normothermic liver perfusion device, the metra®.

Since its launch in Europe in 2018 and in the U.S. in 2022, the metra® has quickly gained acceptance, leading to more organ transplants, the elimination of night-time surgeries, and better patient outcomes.

CEO Craig Marshall remarked, “This new facility is a major milestone, offering world-class facilities and technologies to our stakeholders. It enables us to collaborate in ways that were previously not possible. We are proud to grow within the Oxford business and scientific community and look forward to broader partnerships with commercial and clinical partners.”

Chief Medical Officer and Co-Founder of OrganOx, expressed, “We are thrilled about the future of OrganOx as we continue to push the boundaries of science and medicine with technology aimed at improving the lives of patients with acute or chronic organ failure. This remarkable new facility will support our mission for many years to come.”

Chief Technology Officer and Co-Founder of OrganOx, reflected, “When Peter and I started collaborating in an Oxford University lab over 20 years ago, we could not have imagined a day like this.

This achievement is a testament to the dedication and hard work of numerous researchers, engineers, transplant surgeons, staff, customers, patients, and business partners, whom we celebrate today.”


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress